BDSI announces positive ending up in FDA.

BDSI deferred a open public announcement of this conference pending its receipt and overview of the official a few minutes from the FDA conference, which takes thirty days to get from FDA approximately.. BDSI announces positive ending up in FDA, Meda about REMS program for ONSOLIS BioDelivery Sciences International, Inc. today announced a confident ending up in the U.S. Meals and Medication Administration , Meda and BDSI that happened on Wednesday, July 21, 2010 to go over significant adjustments to the prevailing Risk Evaluation and Mitigation Technique plan for ONSOLIS .Finally, we announced the acquisition of ECG Scanning which will leverage our existing infrastructure and offer usage of additional physician human relationships. ‘With continued demand for our solutions and the progress that we have produced on our strategic goals, we are well positioned to achieve future profitability. Regardless of the cash outlays during the one fourth, we still maintain a healthy cash and investment balance of $37 million without outstanding debt, ultimately offering us the opportunity to continue to invest strategically.’ First Quarter Financial Results Revenue for the 1st quarter 2012 was $27.0 million, a loss of 20.5 percent in comparison to $34.0 million in the first quarter 2011.